• Skip to content (access key 1)
  • Skip to search (access key 7)
FWF — Austrian Science Fund
  • Go to overview page Discover

    • Research Radar
    • Discoveries
      • Emmanuelle Charpentier
      • Adrian Constantin
      • Monika Henzinger
      • Ferenc Krausz
      • Wolfgang Lutz
      • Walter Pohl
      • Christa Schleper
      • Anton Zeilinger
    • scilog Magazine
    • Awards
      • FWF Wittgenstein Awards
      • FWF START Awards
    • excellent=austria
      • Clusters of Excellence
      • Emerging Fields
    • In the Spotlight
      • 40 Years of Erwin Schrödinger Fellowships
      • Quantum Austria
    • Dialogs and Talks
      • think.beyond Summit
    • E-Book Library
  • Go to overview page Funding

    • Portfolio
      • excellent=austria
        • Clusters of Excellence
        • Emerging Fields
      • Projects
        • Principal Investigator Projects
        • Principal Investigator Projects International
        • Clinical Research
        • 1000 Ideas
        • Arts-Based Research
        • FWF Wittgenstein Award
      • Careers
        • ESPRIT
        • FWF ASTRA Awards
        • Erwin Schrödinger
        • Elise Richter
        • Elise Richter PEEK
        • doc.funds
        • doc.funds.connect
      • Collaborations
        • Specialized Research Groups
        • Special Research Areas
        • Research Groups
        • International – Multilateral Initiatives
        • #ConnectingMinds
      • Communication
        • Top Citizen Science
        • Science Communication
        • Book Publications
        • Digital Publications
        • Open-Access Block Grant
      • Subject-Specific Funding
        • AI Mission Austria
        • Belmont Forum
        • ERA-NET HERA
        • ERA-NET NORFACE
        • ERA-NET QuantERA
        • ERA-NET TRANSCAN
        • Alternative Methods to Animal Testing
        • European Partnership Biodiversa+
        • European Partnership ERA4Health
        • European Partnership ERDERA
        • European Partnership EUPAHW
        • European Partnership FutureFoodS
        • European Partnership OHAMR
        • European Partnership PerMed
        • European Partnership Water4All
        • Gottfried and Vera Weiss Award
        • netidee SCIENCE
        • Herzfelder Foundation Projects
        • Quantum Austria
        • Rückenwind Funding Bonus
        • WE&ME Award
        • Zero Emissions Award
      • International Collaborations
        • Belgium/Flanders
        • Germany
        • France
        • Italy/South Tyrol
        • Japan
        • Luxembourg
        • Poland
        • Switzerland
        • Slovenia
        • Taiwan
        • Tyrol–South Tyrol–Trentino
        • Czech Republic
        • Hungary
    • Step by Step
      • Find Funding
      • Submitting Your Application
      • International Peer Review
      • Funding Decisions
      • Carrying out Your Project
      • Closing Your Project
      • Further Information
        • Integrity and Ethics
        • Inclusion
        • Applying from Abroad
        • Personnel Costs
        • PROFI
        • Final Project Reports
        • Final Project Report Survey
    • FAQ
      • Project Phase PROFI
        • Accounting for Approved Funds
        • Labor and Social Law
        • Project Management
      • Project Phase Ad Personam
        • Accounting for Approved Funds
        • Labor and Social Law
        • Project Management
      • Expiring Programs
        • FWF START Awards
  • Go to overview page About Us

    • Mission Statement
    • FWF Video
    • Values
    • Facts and Figures
    • Annual Report
    • What We Do
      • Research Funding
        • Matching Funds Initiative
      • International Collaborations
      • Studies and Publications
      • Equal Opportunities and Diversity
        • Objectives and Principles
        • Measures
        • Creating Awareness of Bias in the Review Process
        • Terms and Definitions
        • Your Career in Cutting-Edge Research
      • Open Science
        • Open Access Policy
          • Open Access Policy for Peer-Reviewed Publications
          • Open Access Policy for Peer-Reviewed Book Publications
          • Open Access Policy for Research Data
        • Research Data Management
        • Citizen Science
        • Open Science Infrastructures
        • Open Science Funding
      • Evaluations and Quality Assurance
      • Academic Integrity
      • Science Communication
      • Philanthropy
      • Sustainability
    • History
    • Legal Basis
    • Organization
      • Executive Bodies
        • Executive Board
        • Supervisory Board
        • Assembly of Delegates
        • Scientific Board
        • Juries
      • FWF Office
    • Jobs at FWF
  • Go to overview page News

    • News
    • Press
      • Logos
    • Calendar
      • Post an Event
      • FWF Informational Events
    • Job Openings
      • Enter Job Opening
    • Newsletter
  • Discovering
    what
    matters.

    FWF-Newsletter Press-Newsletter Calendar-Newsletter Job-Newsletter scilog-Newsletter

    SOCIAL MEDIA

    • LinkedIn, external URL, opens in a new window
    • Twitter, external URL, opens in a new window
    • Facebook, external URL, opens in a new window
    • Instagram, external URL, opens in a new window
    • YouTube, external URL, opens in a new window

    SCILOG

    • Scilog — The science magazine of the Austrian Science Fund (FWF)
  • elane login, external URL, opens in a new window
  • Scilog external URL, opens in a new window
  • de Wechsle zu Deutsch

  

UnVEiL

UnVEiL

Caroline Hutter (ORCID: 0000-0003-2059-4814)
  • Grant DOI 10.55776/PAT6449724
  • Funding program Principal Investigator Projects
  • Status ongoing
  • Start April 1, 2025
  • End March 31, 2028
  • Funding amount € 445,780
  • Project website
  • E-mail

Disciplines

Biology (55%); Clinical Medicine (45%)

Keywords

    Langerhans cell histiocytosis, BRAF, Haematopoiesis, Ipscs, Oncology

Abstract

Langerhans cell histiocytosis (LCH) is a rare disease of the hematopoietic system characterized by CD1a and CD207 positive cells in tumor-like lesions. The spectrum of the disease ranges from spontaneous healing of individual lesions to tumors in multiple organs and systemic inflammation, which requires treatment with chemotherapeutics. What they all share, however, is the activation of the MAPK signaling pathway, which is triggered by a mutation in the BRAF gene (BRAFV600E) in 50-60% of cases. Aside from these specific mutations that activate the MAPK signaling pathway, no other genetic alterations are present. On the one hand, this enables the disease to be modeled relatively easily, as only one mutation needs to be inserted, but on the other hand, this has proven to be a very difficult undertaking. A fundamental problem is that the origin or cell of origin is still unknown. The question therefore arises as to which cell the mutation must be inserted into. The models used so far are almost exclusively mouse models, which fulfill individual aspects of the disease, but do not match the patients` symptoms in essential features. With this project we are not only aiming to clarify the origin of the LCH cells, but also develop a new model system for LCH and other BRAFV600E mutated histiocytoses, such as Erdheim Chester or Rosai Dorfman syndrome. To do this, we will use induced pluripotent stem cells (iPSCs), in which we will heterozygously insert the BRAF mutation using the CRISPR Cas9 method. We will differentiate these cells along the hematopoietic line and analyze the effects of the mutation in the different cell types and understand the developmental path of the hematopoietic cells towards LCH cells. We will also use a combination of two sequencing methods to investigate the influence of the mutation in different cells from lesions or the blood of patients. Using 10x single cell sequencing we will analyze the gene expression of individual cells. We will sequence a part of the cDNA obtained, using long read Oxford Nanopore sequencing. This will allow us to distinguish cells with or without the mutation and compare the respective gene expression patterns. The overall goal of this project is to explore the fundamental mechanisms of how BRAFV600E controls the development of cells towards LCH and to study the interaction of LCH cells with immune cells.

Research institution(s)
  • St. Anna Kinderkrebsforschung GmbH - 100%
Project participants
  • Barbara Maier, CeMM – Forschungszentrum für Molekulare Medizin GmbH , national collaboration partner
  • Christoph Bock, CeMM – Forschungszentrum für Molekulare Medizin GmbH , national collaboration partner
  • Florian Halbritter, St. Anna Kinderkrebsforschung GmbH , national collaboration partner

Discovering
what
matters.

Newsletter

FWF-Newsletter Press-Newsletter Calendar-Newsletter Job-Newsletter scilog-Newsletter

Contact

Austrian Science Fund (FWF)
Georg-Coch-Platz 2
(Entrance Wiesingerstraße 4)
1010 Vienna

office(at)fwf.ac.at
+43 1 505 67 40

General information

  • Job Openings
  • Jobs at FWF
  • Press
  • Philanthropy
  • scilog
  • FWF Office
  • Social Media Directory
  • LinkedIn, external URL, opens in a new window
  • Twitter, external URL, opens in a new window
  • Facebook, external URL, opens in a new window
  • Instagram, external URL, opens in a new window
  • YouTube, external URL, opens in a new window
  • Cookies
  • Whistleblowing/Complaints Management
  • Accessibility Statement
  • Data Protection
  • Acknowledgements
  • Social Media Directory
  • © Österreichischer Wissenschaftsfonds FWF
© Österreichischer Wissenschaftsfonds FWF